TES-1025 is an effective and selective inhibitor of human α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (IC50: 13 nM).

ACMSD (human):13±3 nM

TES-1025 increases NAD+ levels in cellular systems[1].

TES-1025 (0.5 mg/kg; i.v.) shows low blood clearance, with low volumes of distribution and half-lives of about 5.33 h, although the blood concentration of TES-1025 (5 mg/kg) is quantifiable for up to 8 h after oral administration. A good systemic exposure is recorded for TES-1025, with a Cmax of 2570 ng/mL reaches at 2 h. The greater oral exposure of TES-1025 is AUC0-8h of 19 200 h•ng/mL and 36 600 h•ng/mL, respectively[1].